Cyclerion Therapeutics (NASDAQ:CYCN) Shares Up 1.8% – Still a Buy?

Cyclerion Therapeutics, Inc. (NASDAQ:CYCN)’s share price was up 1.8% during mid-day trading on Tuesday . The company traded as high as $4.18 and last traded at $4.00. Approximately 77,890 shares changed hands during mid-day trading, an increase of 143% from the average session volume of 32,010 shares. The stock had previously closed at $3.93.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reiterated a “sell (d-)” rating on shares of Cyclerion Therapeutics in a research report on Friday, July 24th. One investment analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, Cyclerion Therapeutics has an average rating of “Sell”.

Cyclerion Therapeutics Trading Up 1.8%

The company has a market capitalization of $18.72 million, a PE ratio of -2.41 and a beta of 1.76. The firm has a fifty day moving average of $3.59 and a two-hundred day moving average of $2.88.

Cyclerion Therapeutics (NASDAQ:CYCN) last announced its quarterly earnings results on Tuesday, August 4th. The company reported ($0.41) EPS for the quarter, topping analysts’ consensus estimates of ($7.10) by $6.69. Cyclerion Therapeutics had a negative return on equity of 87.96% and a negative net margin of 170.11%. On average, equities analysts expect that Cyclerion Therapeutics, Inc. will post -1.2 EPS for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the company. Two Sigma Investments LP bought a new stake in Cyclerion Therapeutics during the 3rd quarter valued at $31,000. BlackRock Inc. purchased a new stake in Cyclerion Therapeutics during the 2nd quarter valued at $57,000. ADAR1 Capital Management LLC bought a new stake in Cyclerion Therapeutics in the 2nd quarter worth $1,013,000. Finally, Braidwell LP bought a new stake in Cyclerion Therapeutics in the 2nd quarter worth $532,000. 75.62% of the stock is owned by hedge funds and other institutional investors.

About Cyclerion Therapeutics

Cyclerion Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of inhibitors and stimulators of soluble guanylate cyclase (sGC), an intracellular enzyme that plays a critical role in the regulation of vascular tone, cellular proliferation and inflammation. By targeting the nitric oxide (NO)–sGC–cyclic guanosine monophosphate (cGMP) signaling pathway, Cyclerion aims to address a range of cardiometabolic, cardiovascular, pulmonary and neurological disorders with significant unmet medical need.

The company’s lead program, praliciguat, is an oral sGC stimulator investigated for indications such as diabetic nephropathy, metabolic syndrome and heart failure with preserved ejection fraction.